Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an announcement.
Atomo Diagnostics Ltd. has made significant commercial progress in Q1 FY26, highlighted by the submission of the FebriDx test for a CLIA waiver with the US FDA, following successful validation of the Pascal platform in clinical trials. The company has received substantial purchase orders from Lumos, totaling approximately $1 million, as part of their FebriDx agreement. Atomo’s HIV self-test has expanded its distribution channels, launching on Chemist Warehouse’s ecommerce site in Australia and receiving orders from USAID for Ukraine. Additionally, Atomo has secured $1.3 million in new capital to support ongoing business objectives, with a reported revenue of $680k for the quarter.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. is a company operating in the medical diagnostics industry, primarily focusing on rapid diagnostic tests. Their key products include the Pascal platform and the FebriDx test, which are designed to facilitate point-of-care testing. The company is also involved in the development and sale of HIV self-tests and other diagnostic tools, with a market focus on expanding their product reach in the US and international markets.
Average Trading Volume: 1,787,838
Technical Sentiment Signal: Buy
Current Market Cap: A$21.87M
For a thorough assessment of AT1 stock, go to TipRanks’ Stock Analysis page.